News articles about Selecta Biosciences (NASDAQ:SELB) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Selecta Biosciences earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.3330013198675 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of equities analysts recently weighed in on the company. Zacks Investment Research cut Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Canaccord Genuity reaffirmed a “buy” rating and issued a $30.00 price target on shares of Selecta Biosciences in a report on Thursday, January 18th. ValuEngine cut Selecta Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, UBS Group cut Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $23.50.

Shares of Selecta Biosciences (NASDAQ SELB) traded down $0.32 during trading on Monday, hitting $8.49. The company’s stock had a trading volume of 438,500 shares, compared to its average volume of 290,578. Selecta Biosciences has a fifty-two week low of $7.95 and a fifty-two week high of $24.02. The firm has a market capitalization of $189.64, a PE ratio of -2.74 and a beta of -5.56. The company has a quick ratio of 9.48, a current ratio of 9.48 and a debt-to-equity ratio of 0.32.

In other news, insider Earl Sands bought 7,500 shares of Selecta Biosciences stock in a transaction on Friday, November 17th. The stock was acquired at an average price of $10.26 per share, with a total value of $76,950.00. Following the completion of the acquisition, the insider now directly owns 7,500 shares of the company’s stock, valued at $76,950. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Timothy A. Springer bought 57,598 shares of Selecta Biosciences stock in a transaction on Tuesday, November 14th. The shares were purchased at an average cost of $9.27 per share, with a total value of $533,933.46. Following the acquisition, the director now directly owns 461,349 shares of the company’s stock, valued at $4,276,705.23. The disclosure for this purchase can be found here. 41.90% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Selecta Biosciences (SELB) Share Price” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/12/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-selecta-biosciences-selb-share-price.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.